Article Data

  • Views 517
  • Dowloads 148

Original Research

Open Access

Isolated axillary nodal swelling and cancer of unknown primary

  • S. Bertozzi1,*,
  • A.P. Londero2
  • R. Petri1
  • S. Bernardi1

1 Department of Surgery, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia", Udine, Italy

2Clinic of Obstetrics and Gynecology, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia", Udine, Italy

DOI: 10.12892/ejgo2574.2015 Vol.36,Issue 2,April 2015 pp.123-130

Published: 10 April 2015

*Corresponding Author(s): S. Bertozzi E-mail: sere_d.estate@libero.it

Abstract

Introduction: The literature reports rare cases of isolated axillary lymph node metastasis from cancer of unknown primary (CUP). The authors reviewed the prevalence and outcome of patients with isolated axillary nodal swelling suspicious for malignancy affected or not by isolated axillary node metastasis from CUP. Materials and Methods: The authors collected data about 65 patients presented with isolated axillary lymph node swelling who underwent axillary lymph node excisional biopsy for malignancy suspicion, between January 2005 and December 2011, in the absence of any specific diagnosis. Results: Histological examination revealed a metastatic infiltration by an occult solid cancer in 16 cases (24%), ten of which were occult breast cancers. Histological patterns and molecular markers allowed in all cases of occult cancer a probable identification of the primary tumor site, while a definitive diagnosis was possible only in the 56.25% of cases (9/16). The prognosis of these patients was very poor with a five-year overall survival of 28%, and thus very similar to patients affected by Stage IV overt breast cancer. Conclusions: Among occult malignancies presenting with sole axillary lymph node metastasis, breast cancer remains the more probable primary cancer, but many other sites should be taken into consideration by negative breast imaging. Positron-emission tomography computed tomography (PET-CT) resulted helpful in the primary site detection, but has nonetheless a margin of failure. Occult breast cancers behave very similar to Stage IV overt breast cancers, and should be treated accordingly.

Keywords

CUP syndrome; Cancer of unknown primary; Axillary lymph node metastasis; Occult tumor; Breast cancer.

Cite and Share

S. Bertozzi,A.P. Londero,R. Petri,S. Bernardi. Isolated axillary nodal swelling and cancer of unknown primary. European Journal of Gynaecological Oncology. 2015. 36(2);123-130.

References

[1] Pentheroudakis G., Lazaridis G., Pavlidis N.: “Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence”. Breast Cancer Res. Treat., 2010, 119, 1.

[2] Kyokane T., Akashi-Tanaka S., Matsui T., Fukutomi T.: “Clinicopathological characteristics of non-palpable breast cancer presenting as axillary mass”. Breast Cancer, 1995, 2, 105.

[3] Patel J., Nemoto T., Rosner D., Dao T.L., Pickren J.W.: “Axillary lymph node metastasis from an occult breast cancer”. Cancer, 1981, 47, 2923.

[4] Yirmibeo lu E., Tekin E., Memi L., Yamaç D., Taneri F., Erkal H.S.: “A patient with occult breast cancer presenting with an axillary lymph node metastasis and a synchronous contralateral breast cancer”. Breast, 2005, 14, 157.

[5] Kaufmann O., Deidesheimer T., Muehlenberg M., Deicke P., Dietel M.: “Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites”. Histopathology, 1996, 29, 233.

[6] Yamaguchi H., Ishikawa M., Hatanaka K., Uekusa T., Ishimaru M., Nagawa H.: “Occult breast cancer presenting as axillary metastases”. Breast, 2006, 15, 259.

[7] Matsuoka K., Ohsumi S., Takashima S., Saeki T., Aogi K., Mandai K.: “Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients”. Breast Cancer, 2003, 10, 330.

[8] Leibman A.J., Kossoff M.B.: “Mammography in women with axillary lymphadenopathy and normal breasts on physical examination: value in detecting occult breast carcinoma”. AJR Am. J. Roentgenol., 1992, 159, 493.

[9] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Giacomuzzi F., Carbone A.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases”. World J. Surg., 2012, 36, 1915.

[10] Bernardi S., Bertozzi S., Londero A.P.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases: reply”. World J. Surg., 2013, 37, 478.

[11] Postma E.L., Verkooijen H.M., van den Bosch M.A.A.J., van Hillegersberg R.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases: reply”. World J. Surg., 2013, 37, 476.

[12] Pasqual E., Bertozzi S., Bacchetti S., Londero A.: “Effektive Therapie bei peritonealen Neoplasmen mit niedrigem Peritoneal Cancer Index: Die Schwierigkeit der Diagnosesicherung”. Interdisziplinäre Onkologie, 2012, 4, 26.

[13] Tamiolakis D., Antoniou C.: “Axillary nodal metastasis of occult breast primary cancer”. Chirurgia (Bucur)., 2008, 103, 467.

[14] Lloyd M.S., Nash A.G.: “Occult breast cancer”. Ann. R. Coll. Surg. Engl., 2001, 83, 420.

[15] Abe H., Naitoh H., Umeda T., Shiomi H., Tani T., Kodama M., et al.: “Occult breast cancer presenting axillary nodal metastasis: a case report”. Jpn. J. Clin. Oncol., 2000, 30, 185.

[16] Ashikari R., Rosen P.P., Urban J.A., Senoo T.: “Breast cancer presenting as an axillary mass”. Ann. Surg., 1976, 183, 415.

[17] Driul L., Bernardi S., Bertozzi S., Schiavon M., Londero A.P., Petri R.: “New surgical trends in breast cancer treatment: conservative interventions and oncoplastic breast surgery”. Minerva Ginecol., 2013, 65, 289.

[18] Baron P.L., Moore M.P., Kinne D.W., Candela F.C., Osborne M.P., Petrek J.A.: “Occult breast cancer presenting with axillary metastases. Updated management”. Arch. Surg., 1990, 125, 210.

[19] Bernardi S., Bertozzi S., Londero A.P., Angione V., Petri R., Giacomuzzi F.: “Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer”. Nucl. Med. Commun., 2013, 34, 664.

[20] Bernardi S., Londero A.P., Bertozzi S., Driul L., Marchesoni D., Petri R.: “Breast-feeding and benign breast disease”. J. Obstet. Gynaecol., 2012, 32, 58.

[21] Wolff E.F., Martel M., Gwin K., Lannin D.: “Synchronous primary breast and ovarian cancer with ovarian cancer metastases to a breast sentinel lymph node”. Breast J., 2009, 15, 203.

[22] Recine M.A., Deavers M.T., Middleton L.P., Silva E.G., Malpica A.: “Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall”. Am. J. Surg. Pathol., 2004, 28, 1646.

[23] Kayikçiolu F., Boran N., Ayhan A., Güler N.: “Inflammatory breast metastases of ovarian cancer: a case report”. Gynecol. Oncol., 2001, 83, 613.

[24] Ozsaran A.A., Dikmen Y., Terek M.C., Ulukus M., Ozdemir N., Orgüc S., et al.: “Bilateral metastatic carcinoma of the breast from primary ovarian cancer”. Arch. Gynecol. Obstet., 2000, 264, 166.

[25] Manini C., Pietribiasi F., Sapino A., Donadio S.: “Serous cystadenocarcinoma of the ovary with simultaneous breast metastases. Description of a case”. Pathologica, 1998, 90, 152.

[26] Yamasaki H., Saw D., Zdanowitz J., Faltz L.L.: “Ovarian carcinoma metastasis to the breast case report and review of the literature”. Am. J. Surg. Pathol., 1993, 17, 193.

[27] Ibach J.R.: “Carcinoma of the ovary metastatic to breast. a case report and review of the literature”. Arch. Surg., 1964, 88, 410.[28] Khalifeh I., Deavers M.T., Cristofanilli M., Coleman R.L., Malpica A., Gilcrease M.Z.: “Primary peritoneal serous carcinoma presenting as inflammatory breast cancer”. Breast J., 2009, 15, 176.

[29] Ozgüroğlu M., Ersavaşti G., Ilvan S., Hatemi G., Demir G., Demirelli F.H.: “Bilateral inflammatory breast metastases of epithelial ovarian cancer”. Am. J. Clin. Oncol., 1999, 22, 408.

[30] Krishnan E.U., Phillips A.K., Randell A., Taylor B., Garg S.K.: “Bilateral metastatic inflammatory carcinoma in the breast from primary ovarian cancer”. Obstet. Gynecol., 1980, 55, 94S.

[31] Shenoy B.V., Fort L., Benjamin S.P.: “Malignant melanoma primary in lymph node. The case of the missing link”. Am. J. Surg. Pathol., 1987, 11, 140.

[32] Kobayashi G., Cobb C.: “A case of amelanotic spindle-cell melanoma presenting as metastases to breast and axillary lymph node: diagnosis by FNA cytology”. Diagn. Cytopathol., 2000, 22, 246.

[33] Karakousis C.P., Balch C.M., Bartolucci A., Driscoll D.L.: “Is the capacity for lymph node-mediated distant dissemination the same for all nodal groups in malignant melanoma?” Melanoma Res., 1998, 8, 419.

[34] Malafronte P., Sorrells T.: “Lymph node melanosis in a patient with metastatic melanoma of unknown primary”. Arch. Pathol. Lab. Med., 2009, 133, 1332.

[35] Satoh H., Ishikawa H., Kagohashi K., Kurishima K., Sekizawa K.: “Axillary lymph node metastasis in lung cancer”. Med. Oncol., 2009, 26, 147.

[36] Frattaroli F.M., Carrara A., Conte A.M., Pappalardo G.: “Axillary metastasis as first symptom of occult breast cancer: a case report”. Tumori, 2002, 88, 532.

[37] Ko E.Y., Han B.K., Shin J.H., Kang S.S.: “Breast MRI for evaluating patients with metastatic axillary lymph node and initially negative mammography and sonography”. Korean J. Radiol., 2007, 8, 382.

[38] Orel S.G., Weinstein S.P., Schnall M.D., Reynolds C.A., Schuchter L.M., Fraker D.L., et al.: “Breast MR imaging in patients with axillary node metastases and unknown primary malignancy”. Radiology, 1999, 212, 543.

[39] Buchanan C.L., Morris E.A., Dorn P.L., Borgen P.I., Zee K.J.V.: “Utility of breast magnetic resonance imaging in patients with occult primary breast cancer”. Ann. Surg. Oncol., 2005, 12, 1045.

[40] Stella G.M., Senetta R., Cassenti A., Ronco M., Cassoni P.: “Cancers of unknown primary origin: current perspectives and future therapeutic strategies”. J. Transl. Med., 2012, 10, 12.

[41] Beckers M.M.J., Verzijlbergen J.F., van Buul M.M.C., Prins M.H., Biesma D.H.: “The potential role of positron emission tomography in the detection of occult cancer in 25 patients with venous thromboembolism”. Ann. Oncol., 2008, 19, 1203.

[42] Kwee T.C., Basu S., Alavi A.: “PET and PET/CT for unknown primary tumors”. Methods Mol. Biol., 2011, 727, 317.

[43] Takabatake D., Taira N., Aogi K., Ohsumi S., Takashima S., Inoue T., et al.: “Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors”. Breast Cancer, 2008, 15, 181.

[44] Kwee T.C., Basu S., Cheng G., Alavi A.: “FDG PET/CT in carcinoma of unknown primary”. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 635.

[45] Kwee T.C., Kwee R.M.: “Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis”. Eur. Radiol., 2009, 19, 731.

[46] American Cancer Society: “Cancer Facts & Figures 2010”. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf

[47] Thöm I., Rogers C., Andritzky B., Witzel I., Schuch G., Hossfeld D.K., et al.: “Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years”. Onkologie, 2009, 32, 741.

[48] Pavlidis N., Pentheroudakis G.: “Cancer of unknown primary site: 20 questions to be answered”. Ann. Oncol., 2010, 21, vii303.

[49] Pavlidis N., Fizazi K.: “Carcinoma of unknown primary (CUP)”. Crit. Rev. Oncol. Hematol., 2009, 69, 271.

[50] Pavlidis N., Briasoulis E., Hainsworth J., Greco F.A.: “Diagnostic and therapeutic management of cancer of an unknown primary”. Eur. J. Cancer, 2003, 39, 1990.

[51] Cisneros-Reig I., Sastre M.L., Sánchez M.A., Guinot J.N., Giner R.L.G., Salvador-Sanchis J.L., et al.: “Bilateral occult breast carcinoma: a second primary tumour or contralateral tumour metastasis?” Eur. J. Surg., 2001, 167, 312.

[52] Masinghe S.P., Faluyi O.O., Kerr G.R., Kunkler I.H.: “Breast radiotherapy for occult breast cancer with axillary nodal metastases–does it reduce the local recurrence rate and increase overall survival?” Clin. Oncol. (R. Coll. Radiol.), 2011, 23, 95.

[53] Yang T.I.J., Yang Q., Haffty B.G., Moran M.S.: “Prognosis for mammographically occult, early-stage breast cancer patients treated with breast-conservation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 2010, 76, 79.

[54] Barton S.R., Smith I.E., Kirby A.M., Ashley S., Walsh G., Parton M.: “The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy”. Eur. J. Cancer, 2011, 47, 2099.

[55] Varadarajan R., Edge S.B., Yu J., Watroba N., Janarthanan B.R.: “Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis”. Oncology, 2006, 71, 456.

[56] Brill K.L., Brenin D.R.: “Occult breast cancer and axillary mass”. Curr. Treat. Options Oncol., 2001, 2, 149.

[57] Vlastos G., Jean M.E., Mirza A.N., Mirza N.Q., Kuerer H.M., Ames F.C., et al.: “Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases”. Ann. Surg. Oncol., 2001, 8, 425.

[58] Ellerbroek N., Holmes F., Singletary E., Evans H., Oswald M., Mc- Neese M.: “Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin”. Cancer, 1990, 66, 1461.

[59] Bernardi S., Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Dri C., et al.: “Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases”. World J. Surg., 2012, 36, 714.

[60] Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Carbone A., Petri R., Bernardi S.: “Applicability of two different validated models to predict axillary non-sentinel lymph node status by sentinel node biopsy in a single Italian center”. Breast Cancer, 2013, Jul 6. [Epub ahead of print].

[61] Pavlidis N., Pentheroudakis G.: “Cancer of unknown primary site”. Lancet, 2012, 379, 1428.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top